Ultromics, a developer of AI echocardiography software, has raised $55 million in series C financing, which will go toward expanding its portfolio and U.S. presence.
L&G, Allegis Capital, and Lightrock co-led the funding round, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. U.S.-based health systems, including UChicago Medicine's venture investment vehicle, UCM Ventures, and UPMC Enterprises, also participated in the round.
Ultromics uses AI to extract hidden disease signals from standard echocardiograms, aiming for more accurate detection of complex heart conditions without the need for new hardware or disrupting clinical workflows. Its EchoGo platform, cleared by the U.S. Food and Drug Administration (FDA), supports the diagnosis of heart failure with preserved ejection fraction and cardiac amyloidosis.
The company said it is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions. It also highlighted growing adoption and partnerships across flagship institutions, including the University of Chicago Medicine, University Hospitals Cleveland, Northwestern, and the Mayo Clinic.
In late 2024, Ultromics received FDA Breakthrough Device clearance for EchoGo Amyloidosis, followed in 2025 by the launch of EchoGo Score, the latter of which adds AI-driven probability scoring to EchoGo Heart Failure.
